ImmunityBio ($IBRX) Anktiva Marketing Claims Case

Investors can submit applications for the lead plaintiff role.

C.D. California

Court

2:26-cv-03261

Case number

01/19/2026

Class period Start

03/24/2026

Class period End

05/25/2026

Lead Plaintiff motion deadline

$IBRX investors filed a claim against ImmunityBio for allegedly overstating what Anktiva could do and promoting it far beyond its approved use.
After an FDA warning letter said ImmunityBio’s podcast and TV ad made false and misleading claims about Anktiva and promoted unapproved uses, $IBRX fell 21.1% on March 24, 2026.
$IBRX investors can join this case to be notified about potential recovery.
Case Details:

Between January 19, 2026 and March 24, 2026, ImmunityBio told investors Anktiva had broad cancer-fighting potential beyond its approved bladder cancer use. Executives emphasized in a podcast that Anktiva could cure cancer, treat all cancers, prevent cancer after radiation exposure, and help patients after other cancer treatments failed, reinforcing the company’s outlook and product promise.

However, during this period, investors allege the company’s leaders were making sweeping claims about Anktiva that went far beyond what its approval and study results supported. ImmunityBio allegedly failed to disclose Anktiva was approved only for a narrow bladder cancer setting, not for all cancers, lung cancer, or cancer prevention. The available study data did not show that Anktiva alone could cure cancer or keep all patients cancer-free long term, and the company’s promotions also described unapproved uses and injection methods not supported by the label.

Then, on March 24, 2026, an FDA warning letter dated March 13, 2026 was publicized, stating that the company’s podcast and TV ad were false or misleading and that they promoted new uses for which Anktiva lacked approval. $IBRX fell $1.98, closing at $7.42. 

Additional revelations followed on March 24, 2026, including a Bloomberg report highlighting the warning and Soon-Shiong’s statement that Anktiva could treat “all cancers.” 

By March 24, 2026, shares had dropped to $7.42, representing a total decline of 21.1% over the correction period.

Based on these events, $IBRX investors filed a claim against ImmunityBio, alleging the company:
It overstated what Anktiva had been shown to do.
It promoted Anktiva as able to cure, treat, or prevent cancers beyond its approved bladder cancer use, despite lacking support or approval for those claims.
It gave investors a misleading picture of Anktiva’s safety, effectiveness, and approved use, which investors say caused losses after the FDA warning became public.
Investors argue ImmunityBio misled the market about Anktiva’s approved uses and proven benefits, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

03/24/2026

Filing date

03/26/2026

Lead Plaintiff Deadline

05/25/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.